伏立康唑与两性霉素B联合治疗侵袭性肺曲霉病研究进展

Research advance of voriconazole combined with amphotericin B for invasive pulmonary aspergillosis

曲霉是导致免疫缺陷人群发生致命感染的重要病原真菌,其中侵袭性肺曲霉病是临床实践中最常见的感染类型,治疗难度大,死亡率高。本文综述了近年来国内外关于伏立康唑联合两性霉素B治疗侵袭性肺曲霉感染的临床前研究及临床研究结果,旨在探讨伏立康唑联合两性霉素B治疗侵袭性肺曲霉病的疗效和安全性,为侵袭性肺曲霉病的治疗提供临床参考。

Aspergillus is an important pathogenic fungus that causes fatal infections in immunodeficiency populations.Among them,invasive pulmonary aspergillosis is the most common type of infection in clinical practice,which is difficult to treat and has a high mortality rate.This article reviewed the preclinical studies and clinical studies of voriconazole combined with amphotericin B in the treatment of invasive aspergillus infection in recent years,explored the efficacy and safety of voriconazole combined with amphotericin B,and provided a clinical reference for the treatment of invasive pulmonary aspergillosis.